Straits Times Index
3,342.05 -1.30 (-0.04%) Nikkei
39,758.13 +416.59 (+1.06%) Hang Seng
17,807.25 +90.78 (+0.51%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,889.34 +964.03 (+1.58%) CMC Crypto 200
1,290.91 +24.77 (+1.96%)
Indivior PLC (INDV.L)
| Previous close | 1,296.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 2,010.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 625,252 |
| Market cap | 1.712B |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | 425.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Jun 2016 |
| 1y target est | N/A |
- PR Newswire
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
- PR Newswire
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will reconfirm its unchanged FY 2024
